BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nummela P, Leinonen H, Järvinen P, Thiel A, Järvinen H, Lepistö A, Ristimäki A. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. Human Pathology 2016;54:47-54. [DOI: 10.1016/j.humpath.2016.02.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Rim HT, Song JH, Kim ES, Kwon MJ. Mucinous adenocarcinoma arising from a residual supratentorial neurenteric cyst and expressing mutated KRAS: a case report. Hum Pathol 2016;58:146-51. [PMID: 27569299 DOI: 10.1016/j.humpath.2016.05.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Bhangu JS, Taghizadeh H, Braunschmid T, Bachleitner-hofmann T, Mannhalter C. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden. Surgical Oncology 2017;26:395-401. [DOI: 10.1016/j.suronc.2017.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
3 Ma R, Lin YL, Li XB, Yan FC, Xu HB, Peng Z, Li Y. Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study. Diagn Pathol 2021;16:116. [PMID: 34895284 DOI: 10.1186/s13000-021-01177-1] [Reference Citation Analysis]
4 Liang L, Fang J, Han X, Zhai X, Song Y, Lu Y, Zhang Q, Ma R. Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei. Front Oncol 2021;11:594763. [PMID: 34733775 DOI: 10.3389/fonc.2021.594763] [Reference Citation Analysis]
5 Wang X, Gao X, Wang L, Dai Z, Fan B, Cui H, Liu Z. Pseudomyxoma extraperitonei in horseshoe kidney masquerading as renal hilar tumor: a case report. Onco Targets Ther 2018;11:9027-32. [PMID: 30588015 DOI: 10.2147/OTT.S184305] [Reference Citation Analysis]
6 Yan F, Shi F, Li X, Chang H, Jin M, Li Y. Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin. J Int Med Res 2021;49:3000605211022297. [PMID: 34187207 DOI: 10.1177/03000605211022297] [Reference Citation Analysis]
7 Ning S, Yang Y, Wang C, Luo F. Pseudomyxoma peritonei induced by low-grade appendiceal mucinous neoplasm accompanied by rectal cancer: a case report and literature review. BMC Surg 2019;19:42. [PMID: 31023277 DOI: 10.1186/s12893-019-0508-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Fackche N, Schmocker RK, Kubi B, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Powers B, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Gamblin TC, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB. The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. J Gastrointest Surg 2021. [PMID: 33634422 DOI: 10.1007/s11605-021-04953-y] [Reference Citation Analysis]
9 Dohan A, Barral M, Eveno C, Lo Dico R, Kaci R, Pasteur-rousseau A, Soyer P, Pocard M, Bonnin P. Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery. European Journal of Surgical Oncology (EJSO) 2017;43:1932-8. [DOI: 10.1016/j.ejso.2017.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Nummela P, Heiskanen A, Kytölä S, Haglund C, Lepistö A, Satomaa T, Ristimäki A. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei. Glycobiology 2021;31:211-22. [PMID: 33539510 DOI: 10.1093/glycob/cwaa079] [Reference Citation Analysis]
11 Lopes A, de Mello ES, Mendoza Lopez RV, Leonardi PC, Ribeiro U Jr. Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei. J Surg Res 2022;274:68-76. [PMID: 35123285 DOI: 10.1016/j.jss.2022.01.001] [Reference Citation Analysis]
12 Ye S, Zheng S. Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma Peritonei: A Literature Review. Am J Clin Oncol 2022;45:223-31. [PMID: 35446281 DOI: 10.1097/COC.0000000000000911] [Reference Citation Analysis]
13 Saarinen L, Nummela P, Leinonen H, Heiskanen A, Thiel A, Haglund C, Lepistö A, Satomaa T, Hautaniemi S, Ristimäki A. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei. Mol Cell Proteomics 2018;17:2107-18. [PMID: 30072579 DOI: 10.1074/mcp.RA118.000615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ; PSOGI. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 2021;47:11-35. [PMID: 32199769 DOI: 10.1016/j.ejso.2020.02.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]